Announcements Trials
Browse Landscape

Phase

Phase 1/2 4

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 4Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Mesothelioma 6Solid Tumor 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Mesothelioma, Malignant 4Advanced Solid Tumors 4Solid Tumors 3Stomach Neoplasms 2Solid Tumor, Adult 2Lung Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Thymoma 1Select Advanced Solid Tumors 1Sarcoma 1Relapsed Pediatric Solid Tumor 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelin-positive Advanced Refractory Solid Tumors 1Mesothelin-positive Advanced Malignant Solid Tumors 1KRAS G12V 1

Interventions

Cisplatin 57Pemetrexed 46pembrolizumab 18Nivolumab 15Carboplatin 15Gemcitabine 14Cyclophosphamide 13Radiotherapy 10Drug Therapy 9atezolizumab 8Platinum 7Ipilimumab 7Doxorubicin 7durvalumab 61,2-diaminocyclohexaneplatinum II citrate 6tremelimumab 5sodium thiosulfate 5Vinorelbine 5Radiotherapy, Intensity-Modulated 5Interleukin-2 5Chemotherapy, Adjuvant 5Cerebral Decortication 5sargramostim 4fludarabine 4defactinib 4aldesleukin 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3cediranib 3Photochemotherapy 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × fludarabine × Other solid neoplasm × Clear all
NCT07510815 2026-04-06

DUAL-MESO-NK

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡